This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 12496 results found since Jan 2013.
Neonatal opioid toxicity: opioid withdrawal (abstinence) syndrome with emphasis on pharmacogenomics and respiratory depression
Arch Toxicol. 2023 Aug 3. doi: 10.1007/s00204-023-03563-8. Online ahead of print.ABSTRACTThe increasing use of opioids in pregnant women has led to an alarming rise in the number of cases of neonates with drug-induced withdrawal symptoms known as neonatal opioid withdrawal syndrome (NOWS). NOWS is a toxic heterogeneous condition with many neurologic, autonomic, and gastrointestinal symptoms including poor feeding, irritability, tachycardia, hypertension, respiratory defects, tremors, hyperthermia, and weight loss. Paradoxically, for the management of NOWS, low doses of morphine, methadone, or buprenorphine are administered...
Source: Archives of Toxicology - August 3, 2023 Category: Toxicology Authors: Brian A Baldo Source Type: research
BUPRENORPHINE AND NALOXONE tablet Rhodes Pharmaceuticals L.P.
Updated Date: Wed, 02 Aug 2023 00:00:00 EDT
Source: DailyMed Drug Label Updates - August 2, 2023 Category: Drugs & Pharmacology Source Type: alerts
Subcutaneous administration of hydromorphone (0.2 mg/kg) provides antinociception in ferrets (Mustela putorius furo)
Am J Vet Res. 2023 Aug 5:1-7. doi: 10.2460/ajvr.23.05.0099. Online ahead of print.ABSTRACTOBJECTIVE: To evaluate antinociceptive efficacy of SC administration of hydromorphone hydrochloride and buprenorphine hydrochloride in ferrets (Mustela putorius furo).ANIMALS: 14 healthy adult ferrets (6 neutered males, 8 spayed females).METHODS: In a randomized, blind, controlled, complete crossover design, all 14 ferrets received a single, SC injection of hydromorphone low dose (0.1 mg/kg), hydromorphone high dose (0.2 mg/kg), buprenorphine low dose (0.02 mg/kg), buprenorphine high dose (0.04 mg/kg), or saline solution (0.2 mL/kg). ...
Source: American Journal of Veterinary Research - August 1, 2023 Category: Veterinary Research Authors: Isabelle Desprez Andrew Crookes Nicola Di Girolamo Barbara Ambros Source Type: research
Reliability of urine drug testing among patients on buprenorphine transdermal patch
CONCLUSION: In addition to the UDT, a thorough history, screening for NMOU, physical exam, a review of PDMP, and a good understanding of opioid metabolism are necessary to help guide pain management.PMID:37525588 | DOI:10.1017/S147895152300086X
Source: Palliative and Supportive Care - August 1, 2023 Category: Palliative Care Authors: Jaya Amaram-Davila Akhila Reddy Matthew D Clark Anita Nancherla Joseph Arthur Eduardo Bruera Source Type: research
Subcutaneous administration of hydromorphone (0.2 mg/kg) provides antinociception in ferrets (Mustela putorius furo)
Am J Vet Res. 2023 Aug 5:1-7. doi: 10.2460/ajvr.23.05.0099. Online ahead of print.ABSTRACTOBJECTIVE: To evaluate antinociceptive efficacy of SC administration of hydromorphone hydrochloride and buprenorphine hydrochloride in ferrets (Mustela putorius furo).ANIMALS: 14 healthy adult ferrets (6 neutered males, 8 spayed females).METHODS: In a randomized, blind, controlled, complete crossover design, all 14 ferrets received a single, SC injection of hydromorphone low dose (0.1 mg/kg), hydromorphone high dose (0.2 mg/kg), buprenorphine low dose (0.02 mg/kg), buprenorphine high dose (0.04 mg/kg), or saline solution (0.2 mL/kg). ...
Source: American Journal of Veterinary Research - August 1, 2023 Category: Veterinary Research Authors: Isabelle Desprez Andrew Crookes Nicola Di Girolamo Barbara Ambros Source Type: research
Dental Disorders Reported to the FDA Adverse Event Reporting System in Association with Buprenorphine: An Analysis by Ingredient Composition and Route of Administration
CONCLUSION: Subject to the limitations of spontaneous adverse event data, this study identified significantly disproportionate reporting of dental disorders to FAERS among patients treated with buprenorphine-containing medications, including formulations administered by sublingual, buccal and oral routes. These findings are consistent with prior data and suggest that regular oral care and proper dental hygiene be emphasized for patients undergoing therapy with orally dissolving buprenorphine.PMID:37526182 | DOI:10.2174/1574886318666230731151447
Source: Current Drug Safety - August 1, 2023 Category: Drugs & Pharmacology Authors: Richard H Woods Source Type: research
Reliability of urine drug testing among patients on buprenorphine transdermal patch
CONCLUSION: In addition to the UDT, a thorough history, screening for NMOU, physical exam, a review of PDMP, and a good understanding of opioid metabolism are necessary to help guide pain management.PMID:37525588 | DOI:10.1017/S147895152300086X
Source: Pain Physician - August 1, 2023 Category: Anesthesiology Authors: Jaya Amaram-Davila Akhila Reddy Matthew D Clark Anita Nancherla Joseph Arthur Eduardo Bruera Source Type: research
Dental Disorders Reported to the FDA Adverse Event Reporting System in Association with Buprenorphine: An Analysis by Ingredient Composition and Route of Administration
CONCLUSION: Subject to the limitations of spontaneous adverse event data, this study identified significantly disproportionate reporting of dental disorders to FAERS among patients treated with buprenorphine-containing medications, including formulations administered by sublingual, buccal and oral routes. These findings are consistent with prior data and suggest that regular oral care and proper dental hygiene be emphasized for patients undergoing therapy with orally dissolving buprenorphine.PMID:37526182 | DOI:10.2174/1574886318666230731151447
Source: Current Drug Safety - August 1, 2023 Category: Drugs & Pharmacology Authors: Richard H Woods Source Type: research
Reliability of urine drug testing among patients on buprenorphine transdermal patch
CONCLUSION: In addition to the UDT, a thorough history, screening for NMOU, physical exam, a review of PDMP, and a good understanding of opioid metabolism are necessary to help guide pain management.PMID:37525588 | DOI:10.1017/S147895152300086X
Source: Palliative and Supportive Care - August 1, 2023 Category: Palliative Care Authors: Jaya Amaram-Davila Akhila Reddy Matthew D Clark Anita Nancherla Joseph Arthur Eduardo Bruera Source Type: research
Buprenorphine
Source: Reactions Weekly - August 1, 2023 Category: Drugs & Pharmacology Source Type: research
Buprenorphine/naloxone/paracetamol
Source: Reactions Weekly - August 1, 2023 Category: Drugs & Pharmacology Source Type: research
Buprenorphine
Source: Reactions Weekly - August 1, 2023 Category: Drugs & Pharmacology Source Type: research
